Aethlon Medical Inc. Approves 100,000‑Share Increase to Equity Plan

What Happened Aethlon Medical, Inc. (AEMD) announced via Form 8‑K that its stockholders approved an amendment to the company's 2020 Equity Incentive Plan to add 100,000 shares to the plan's authorized reserve. The Board had approved the Plan Amendment on July 10, 2026, subject to stockholder approval, and the amendment became effective October 1, 2026. The company filed related disclosure in its Definitive Proxy Statement on August 21, 2026.

Key Details

• Stockholder vote approved a Plan Amendment increasing the 2020 Equity Incentive Plan by 100,000 shares.
• Board approval occurred July 10, 2026; stockholder approval completed and effective October 1, 2026.
• The Amended 2020 Plan and forms of grants are attached to the 8‑K (Exhibit 10.1).
• Disclosure about the amendment was included in the company’s Schedule 14A proxy statement filed August 21, 2026.

Why It Matters This change increases the pool of shares available for equity awards (options, restricted stock, etc.), giving the company more flexibility to grant incentives to employees, directors, and consultants. For investors, the amendment can mean potential future dilution if new awards are issued and exercised, but it is a routine corporate action used to support hiring and retention. The filing does not announce any specific grant amounts or financial impacts beyond the increase in authorized shares.